The Quantellect read.As of Nov 19, 2026, 10 active firms cover Enliven Therapeutics Inc: 10 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $70.00 to $82.00, so the covering firms are broadly aligned. The average target of $75.44 sits 68% above the current $44.89. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 8 to 10 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.45 next quarter toward $-1.99 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Buy
Strong Buy00%
Buy10100%
Neutral00%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$75.44
+68.1% upside
Average target across 9 active firms as of Nov 19, 2026 vs $44.89 current
Highest Target$82.00
Average Target$75.44
Lowest Target$70.00
Detailed analyst forecasts for ELVN
Showing 1–10 of 10 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 10 of 10 active firms rate ELVN a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ELVN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.45
Range $-0.49 – $-0.42 · 5 analysts · +19% YoY
Next period, 5 analysts expect Enliven Therapeutics Inc. to earn $-0.45 a share (range $-0.49 – $-0.42), versus $-0.38 a year earlier. Full-year consensus is $-1.66, growing to $-1.99 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $5.0K next year.
Top analysts covering Enliven Therapeutics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ELVN.
#1
Michael Schmidt
Guggenheim · Rank #4
Buy
$78.00+73.8% to target
Overall win rate
53%
+ Follow
#2
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$73.00+62.6% to target
Overall win rate
42%
+ Follow
#3
Justin Zelin
BTIG · Rank #495
Buy
$45.00+0.2% to target
Overall win rate
30%
+ Follow
#4
Salveen Richter
Goldman Sachs
Buy
$80.00+78.2% to target
Coverage
—
+ Follow
#5
DA
Dara Azar
Stifel Nicolaus
Buy
$82.00+82.7% to target
Coverage
—
+ Follow
ELVN stock forecast FAQ
What is ELVN's average 12-month price target?+
The 9 active firms with a live target average $75.44 for Enliven Therapeutics Inc. over the next 12 months, ranging from a $82.00 high to a $70.00 low, as of Nov 19, 2026.
Is ELVN stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 10 active firms as of Nov 19, 2026, 10 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ELVN?+
The Street-high target is $82.00 (Stifel), and the Street-low is $70.00 (Morgan Stanley). The average of all 9 active-firm targets is $75.44.
How many active Wall Street firms cover ELVN?+
10 active firms have a recognized rating on Enliven Therapeutics Inc. as of Nov 19, 2026, and 9 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ELVN?+
Among analysts who currently cover ELVN, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #4). Their current call is Buy with a $78.00 target.
What is Enliven Therapeutics Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.45 per share (range $-0.49 – $-0.42) across 5 analysts. Full-year EPS is projected at $-1.66, rising to $-1.99 the following year.
How much revenue is Enliven Therapeutics Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $5.0K next year.
Have analysts been upgrading or downgrading ELVN lately?+
As of Nov 19, 2026, 10 of 10 active firms rate ELVN a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ELVN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.